PDF(Sci-hub)
Abstract：
The Standardized Uptake Value (SUV) in single lesions on 18F-FDG PET/CT scans and serum S-100B concentrations are inversely associated with disease-free survival in stage IV melanoma. The aim of this study was to assess the association between biomarkers (S-100B, LDH) and the PET-derived metrics SUVmean/max, metabolic active tumor volume (MATV), and total lesion glycolysis (TLG) in stage IV melanoma in order to understand what these biomarkers reflect and their possible utility for follow-up.
In 52 stage IV patients the association between PET-derived metrics and the biomarkers S-100B and LDH was assessed and the impact on survival analyzed.
S-100B was elevated (>0.15 μg/l) in 37 patients (71%), LDH in 11 (21%). There was a correlation between S-100B and LDH (R2 = 0.19). S-100B was correlated to both MATV (R2 = 0.375) and TLG (R2 = 0.352), but LDH was not. Higher MATV and TLG levels were found in patients with elevated S-100B (p < 0.001) and also in patients with elevated LDH (>250 U/l) (p < 0.001). There was no association between the biomarkers and SUVmean/max. Survival analysis indicated that LDH was the only predictor of melanoma-specific survival.
In newly diagnosed stage IV melanoma patients S-100B correlates with 18F-FDG PET/CT derived MATV and TLG in contrast to LDH, is more often elevated than LDH (71% vs. 21%) and seems to be a better predictor of disease load and disease progression. However, elevated LDH is the only predictor for survival. The biomarkers, S-100B and LDH appear to describe different aspects of the extent of metastatic disease and of tumornecrosis.
In 52 stage IV patients the association between PET-derived metrics and the biomarkers S-100B and LDH was assessed and the impact on survival analyzed.
S-100B was elevated (>0.15 μg/l) in 37 patients (71%), LDH in 11 (21%). There was a correlation between S-100B and LDH (R2 = 0.19). S-100B was correlated to both MATV (R2 = 0.375) and TLG (R2 = 0.352), but LDH was not. Higher MATV and TLG levels were found in patients with elevated S-100B (p < 0.001) and also in patients with elevated LDH (>250 U/l) (p < 0.001). There was no association between the biomarkers and SUVmean/max. Survival analysis indicated that LDH was the only predictor of melanoma-specific survival.
In newly diagnosed stage IV melanoma patients S-100B correlates with 18F-FDG PET/CT derived MATV and TLG in contrast to LDH, is more often elevated than LDH (71% vs. 21%) and seems to be a better predictor of disease load and disease progression. However, elevated LDH is the only predictor for survival. The biomarkers, S-100B and LDH appear to describe different aspects of the extent of metastatic disease and of tumornecrosis.
摘要：
在18F-FDGPET/CT扫描上单个病变的标准化摄取值(SUV)和血清S-100B浓度与IV期黑素瘤的无病存活呈负相关。这项研究的目的是评估生物标志物(S-100B，LDH)和PET得出的指标SUVmean/max，代谢活性肿瘤体积（MATV），和IV期黑色素瘤的总病变糖酵解（TLG），以了解这些生物标志物反映了什么，以及它们对随访的可能效用。
在52例IV期患者中，评估了PET衍生指标与生物标志物S-100B和LDH之间的关联，并分析了对生存的影响。
37例患者（71%）S-100B升高（>0.15μg/l），LDH在11(21%)。S-100B与LDH之间存在相关性(R2=0.19)。S-100B与MATV（R2=0.375）和TLG（R2=0.352）均相关，但LDH不是。在S-100B升高的患者（p<0.001）以及LDH升高的患者（>250U/l）（p<0.001）中发现了较高的MATV和TLG水平。生物标志物与SUVmean/max之间没有关联。生存分析表明LDH是黑色素瘤特异性生存的唯一预测因子。
在新诊断的IV期黑色素瘤患者中，与LDH相比，S-100B与18F-FDGPET/CT衍生的MATV和TLG相关，比LDH更经常升高(71%vs.21％），似乎可以更好地预测疾病负荷和疾病进展。然而,LDH升高是生存的唯一预测因子。生物标志物，S-100B和LDH似乎描述了转移性疾病和肿瘤坏死程度的不同方面。
在52例IV期患者中，评估了PET衍生指标与生物标志物S-100B和LDH之间的关联，并分析了对生存的影响。
37例患者（71%）S-100B升高（>0.15μg/l），LDH在11(21%)。S-100B与LDH之间存在相关性(R2=0.19)。S-100B与MATV（R2=0.375）和TLG（R2=0.352）均相关，但LDH不是。在S-100B升高的患者（p<0.001）以及LDH升高的患者（>250U/l）（p<0.001）中发现了较高的MATV和TLG水平。生物标志物与SUVmean/max之间没有关联。生存分析表明LDH是黑色素瘤特异性生存的唯一预测因子。
在新诊断的IV期黑色素瘤患者中，与LDH相比，S-100B与18F-FDGPET/CT衍生的MATV和TLG相关，比LDH更经常升高(71%vs.21％），似乎可以更好地预测疾病负荷和疾病进展。然而,LDH升高是生存的唯一预测因子。生物标志物，S-100B和LDH似乎描述了转移性疾病和肿瘤坏死程度的不同方面。
